Neuroprotective efficacy of 5HT1A agonist DU123015 and positive control MK-801 in the 120 minutes distal MCAo model. The body weights (absolute weight in grams ± SEM) did not differ significantly for DU123015- (A) or MK-801-treated subjects (B). (C) No significant differences on neurological deficit were found for DU123015- (D) or MK-801-treated animals (E). No significant differences between groups were observed for oedema corrected MRI lesion volumes for DU123015-treated animals and glucosaline control treated animals (F). Also, no significant reduction in lesions was detected using the positive control compound MK-801.